ACTUALIDAD

A multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety monitoring three months after treatment in patients with moderate to severe xerophthalmia.

 

RESEARCHER:

Dr. Jesús Merayo Lloves

 ACTIVO 

 

A multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety monitoring three months after treatment in patients with moderate to severe xerophthalmia.


INDICATION: Moderate to severe dry eye
TREATMENT: Ciclosporina
PROMOTOR: Mc2 biotec- Iris Pharma
Déjanos tus datos
Nos pondremos en contacto contigo
Please enable JavaScript in your browser to complete this form.
Casillas de verificación
REQUEST APPOINTMENT
We will contact you
Please enable JavaScript in your browser to complete this form.
Casillas de verificación